Delivery of Essential Medicines to Primary Care Institutions and its Association with Procurement Volume and Price: A Case Study in Hubei Province, China

Applied Health Economics and Health Policy

Volumn 15, Issue 1, 2017, Pages 57-64

  Tang, Yuqing ^a   Liu, Chaojie ^b,c   Zhang, Xinping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHINA; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; MEDICINE; PRIMARY MEDICAL CARE; REGRESSION ANALYSIS; RELIABILITY; UNCERTAINTY; DRUG COST; ECONOMICS; HUMAN; PRIMARY HEALTH CARE; PROCEDURES; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

ESSENTIAL DRUG;

CHINA; DRUG COSTS; DRUGS, ESSENTIAL; HUMANS; PRIMARY HEALTH CARE;

EID: 84986316047     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-016-0276-8     Document Type: Article

References (36)

1. World Health Organization. Essential medicines. Geneva: World Health Organisation; 2012. Available at: http://www.who.int/medicines/services/essmedicines_def/en/index.html. Accessed 14 Apr 2014.
2. Mackintosh M, Chaudhuri S, Mujinja P. Can NGOs regulate medicines markets? Social enterprise in wholesaling, and access to essential medicines. Glob Health. 2011;7(1):1–13.
3. Attaran A. How do patents and economic policies affect access to essential medicines in developing countries? Health Aff (Millwood). 2004;23(3):155–66.
4. ‘t Hoen E. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. Chic J Int Law. 2002;3(1):27–46.
5. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–9.
6. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007;85:279–88.
7. Sun Q. A survey of medicine prices, availability, affordability and price components in Shandong province, China. Shandong: Center for Health Management and Policy, Shandong University; 2005.
8. Yang H, Dib HH, Zhu M, Qi G, Zhang X. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Health Policy Plan. 2010;25(3):219–29.
9. Wang X, Fang Y, Yang S, Jiang M, Yan K, Wu L, et al. Access to paediatric essential medicines: a survey of prices, availability, affordability and price components in shaanxi province, china. PLoS One. 2014;9(3):e90365.
10. Nunan M, Duke T. Effectiveness of pharmacy interventions in improving availability of essential medicines at the primary healthcare level. Trop Med Int Health. 2011;16(5):647–58.
11. Wagstaff A, Yip W, Lindelow M, Hsiao WC. China’s health system and its reform: a review of recent studies. Health Econ. 2009;18(Suppl 2):S7–23.
12. World Health Organization. How to develop and implement a national drug policy. 2nd ed. Malta: World Health Organization; 2001. p. 6–7.
13. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.
14. The State Council of China. Implementation plan for the recent priorities of the health care system reform (2009–2011). Beijing: State Council of China; 2009.
15. Yip WC, Hsiao WC, Chen W, Hu S, Ma J, Maynard A. Early appraisal of China’s huge and complex health-care reforms. Lancet. 2012;379(9818):833–42.
16. Xu J, Wang W, Li Y, Zhang J, Pavlova M, Liu H, et al. Analysis of factors influencing the outpatient workload at Chinese health centres. BMC Health Serv Res. 2010;10:151.
17. Hubei Statistical Bureau. Hubei provincial statistical yearbook. Wuhan: Hubei Statistical Bureau; 2011.
18. Ministry of Health of the People’s Republic of China. Opinions on the implementation of national essential medicines policies. Beijing: Ministry of Health; 2009.
19. Barber SL, Huang B, Santoso B, Laing R, Paris V, Wu C. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. J Glob Health. 2013;3(1):010303.
20. General Office of the State Council. Opinions on establishing and implementation of compensation mechanism of the primary health care institutions. Beijing: State Council; 2010.
21. Tang Y, Zhang X, Yang C, Yang L, Wang H. Application of propensity scores to estimate the association between government subsidy and injection use in primary health care institutions in China. BMC Health Serv Res. 2013;13:183.
22. Wuhan Municipal Development and Reform Commission. Hubei Province achieve full coverage of essential medicines system in advance. Wuhan: Wuhan Government; 2011. Available at: http://www.whdrc.gov.cn/article/20111020091117584_05.html. Accessed 14 Apr 2014.
23. Liu W, Wang L, Liu P, Wang W. Influences of the policy of essential drugs “Zero-profit” sales on retail pharmacies and countermeasures. China Pharm. 2011;22(36):3364–6.
24. Jiao T, Feng Z. Analysis of influencing factors of configuration and distribution link of essential drugs and countermeasures. China Pharm. 2012;16:1474–6.
25. Bureau HS. Hubei provincial statistical yearbook. Wuhan: Hubei Statistical Bureau; 2014.
26. Statistical Bulletin. Available at: http://www.hbjycg.com/HomePage/ShowList.aspx?CatalogId=40. Accessed 6 Aug 2016.
27. Jamaludin KR, Talib A, Tan CH. An improvement to the performance measurement system of the logistics operation. J Inst Eng Malaysia. 2004;68(2):41–6.
28. Petrovic-Lazarevic S, Sohal AS, Perry M. Supply chain improvement initiatives in the Australian textiles, clothing, footwear and leather industry: a field study. Int J Logist Syst Manag. 2007;3(1):1–19.
29. Hubei Provincial Government Office. Online procurement and payment management of essential medicines in Hubei primary health care institutions. http://gkml.hubei.gov.cn/auto5472/auto5473/201405/t20140513_500288.html. Accessed 30 Aug 2014.
30. Koenker R, Bassett G. Regression quantiles. Econometrica. 1978;46(1):33–50.
31. Radford S, Eames C, Brennan K, Lambert G, Crane C, Williams JMG, et al. Trait mindfulness as a limiting factor for residual depressive symptoms: an explorative study using quantile regression. PLoS One. 2014;9(7):e100022.
32. Liu H, Zhang C. Comparative study on service efficiency of China’s urban and rural health systems. China Soft Sci. 2011;10:102–12.
33. Montaner J, O’Shaughnessy M, Schechter M. Industry sponsored clinical research: a double-edged sword. Lancet. 2001;358:1893–5.
34. Abraham J. The pharmaceutical industry as a political player. Lancet. 2002;360:1498–502.
35. Management Science for Health (2012) Managing procurement. Management Science for Health, Medford Massachusetts. http://www.msh.org/sites/msh.org/files/mds3-ch18-procurement-mar2012.pdf. Accessed 30 June 2014.
36. World Health Organization. Department of Essential Drugs and Medicines Policy, UNICEF, United Nations Population Fund, World Bank. Operational principles for good pharmaceutical procurement. Interagency guidelines. Geneva: World Health Organization; 1999.